Skip to main content
. 2020 Apr 13;9(4):952. doi: 10.3390/cells9040952

Figure 2.

Figure 2

Antineoplastic activity of BLR100 or BLR200 on PDAC. (A) Schedule of treatment. The peptides were administered three times per week at 4.5 µg/kg, at the indicated day (black arrows). Dotted arrows indicate mice sacrifice and analysis on days 14 and 25. (B) Tumor in the pancreas of mice 4 days after tumor transplantation (H&E staining, scale bar 100 µm). (C) Tumor burden (evaluated as pancreas weight) in mice bearing FC1199 orthotopic tumors treated with vehicle, BLR100, or BLR 200 on day 14 (n = 5) or 25 (n = 7). Dotted line indicates the weight of pancreas in healthy mice. (D) Effect of treatments on ascites formation. Data are the percentage of mice presenting (black) or not (gray) ascites on day 25 (n = 7). (E) Tumor burden in mice treated with a scramble peptide, BLR100, or BLR200 (10 µg/kg) and sacrificed 25 days after tumor transplantation (n = 8). Dotted line indicates the weight of the pancreas in healthy mice. In C and E, data are mean ± SEM. One way ANOVA and Tukey’s, ** p < 0.005; * p < 0.05. (F) Effect of BLR100 or BLR200 on FC1199 cell proliferation in vitro. Data are the percentage of control proliferation, mean ± SEM of values from 2 independent experiments.